NVS' Afinitor Gets FDA Panel Backing - Zacks.com PDF Print
Zacks.com
Novartis (NVS - Snapshot Report) recently received a positive recommendation from an advisory panel of the US Food and Drug Administration (FDA) for expanding the use of its renal cancer drug Afinitor. The approval is sought for the treatment of

...

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.